Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 11/20 | 0.64 |
| ▸ | HTR3A | P46098 | 5/20 | 0.52 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.52 |
| ▸ | HTR3B | O95264 | 4/20 | 0.52 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.52 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7690581 | 0.90 | CHRNA7 (0.60) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6878865 | 0.85 | CHRNA7 (0.67) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6882869 | 0.85 | CHRNA7 (0.67) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6880981 | 0.84 | CHRNA7 (0.64) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL7706552 | 0.84 | CHRNA7 (0.66) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6882795 | 0.84 | CHRNA7 (0.66) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6882767 | 0.82 | CHRNA7 (0.64) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6879836 | 0.82 | CHRNA7 (0.64) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6882631 | 0.82 | CHRNA7 (0.62) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6882836 | 0.80 | CHRNA7 (0.60) | CHRNA7HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052389-A1 | Treating a disease or condition in a mammal, wherein the alpha 7 nicotinic-acetylcholine receptor is implicated | PHARMACIA & UPJOHN COMPANY | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052389-A1 | Treating a disease or condition in a mammal, wherein the alpha 7 nicotinic-acetylcholine receptor is implicated | CHRNA7, CHRNA1, CHRNB1 | CHRNA7 1/4885HTR3A 882/4885HTR3E 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.